利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

76 条记录 (耗时 0.024 秒)

    Systems and methods for applying a selected treatment agent into contact with tissue
    73.
    发明申请
    Systems and methods for applying a selected treatment agent into contact with tissue 有权
    将选定的处理剂施用于与组织接触的系统和方法

    公开(公告)号：US20080033374A1

    公开(公告)日：2008-02-07

    申请号：US11906457

    申请日：2007-10-02

    申请人： David Utley ,  John Gaiser ,  Rachel Croft

    发明人： David Utley ,  John Gaiser ,  Rachel Croft

    IPC分类号： A61M25/06 ,  A61M25/09

    CPC分类号： A61B18/1492 ,  A61B18/1477 ,  A61B2018/00214 ,  A61B2018/00232 ,  A61B2018/00553 ,  A61B2018/00797 ,  A61B2018/00815 ,  A61B2018/1425 ,  A61M25/0084

    摘要： Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and/or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and/or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

    摘要翻译： 通过将一种或多种治疗剂施用于存在异常神经症状或异常组织病状的区域处或附近的组织来治疗胃肠道疾病的系统和方法。 选择治疗剂以破坏异常神经通路和/或减轻异常组织状况。 治疗剂可以包括至少一种细胞因子和/或至少一种香草酸化合物以引起所需的组织应答。 系统和方法可以用作主要治疗方式，或作为新辅助治疗方式。

    Systems and methods for tissue mapping and ablation
    76.
    发明授权
    Systems and methods for tissue mapping and ablation 失效
    用于组织测绘和消融的系统和方法

    公开(公告)号：US5916213A

    公开(公告)日：1999-06-29

    申请号：US794804

    申请日：1997-02-04

    申请人： Michel Haissaguerre ,  Walter Bruszewski ,  Le Le ,  Mark Maguire ,  John Gaiser ,  Huu Nguyen

    发明人： Michel Haissaguerre ,  Walter Bruszewski ,  Le Le ,  Mark Maguire ,  John Gaiser ,  Huu Nguyen

    IPC分类号： A61B5/0402 ,  A61B18/08 ,  A61B18/12 ,  A61B18/14 ,  A61M25/00 ,  A61B17/39

    CPC分类号： A61B18/08 ,  A61B18/1492 ,  A61B2017/003 ,  A61B2017/2945 ,  A61B2018/00011 ,  A61B2018/00029 ,  A61B2018/0016 ,  A61B2018/00214 ,  A61B2018/00351 ,  A61B2018/00577 ,  A61B2018/00839 ,  A61B2018/00898 ,  A61B2018/0091 ,  A61B2018/1432 ,  A61B2018/1467 ,  A61B2018/1472 ,  A61B2218/002

    摘要： A steerable electrophysiology catheter includes a shaft having a distal ablation segment with one or more electrodes coupled to a source of electrical energy by a connector extending through the shaft. The distal ablation segment of the shaft is movable between a collapsed configuration sized for percutaneous introduction into the patient and/or endoluminal delivery to the target site and an expanded configuration, in which the distal ablation segment forms a substantially continuous surface transverse to the shaft axis for engaging the heart tissue and creating a linear lesion thereon. The catheter includes one or more force element(s) positioned to apply an axial force between the distal and proximal ends of the ablation segment. The force element(s) provide a sufficiently uniform force against the distal ablation segment to establish continuous contact pressure between the electrodes and the patient's heart tissue. This contact pressure allows the surgeon to engage the entire length of the distal ablation segment against the heart tissue to provide a relatively long linear lesion on this tissue.

    摘要翻译： 可引导的电生理导管包括具有远端消融段的轴，其具有通过延伸穿过轴的连接器而与电源耦合的一个或多个电极。 轴的远端消融段可在被定形成经皮引入患者体内和/或腔内递送到目标部位的膨胀构型和扩张构型之间移动，其中远侧消融段形成横向于轴线的基本上连续的表面 用于接合心脏组织并在其上产生线性损伤。 导管包括定位成在消融段的远端和近端之间施加轴向力的一个或多个力元件。 力元件提供足够均匀的力抵抗远端消融段，以在电极和患者的心脏组织之间建立连续的接触压力。 该接触压力允许外科医生将远端消融段的整个长度接合心脏组织以在该组织上提供相对较长的线性损伤。